Syndax Pharmaceuticals (SNDX) Operating Income (2015 - 2026)

Syndax Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$34.2 million for Q1 2026.

• On a quarterly basis, Operating Income rose 59.17% year-over-year to -$34.2 million in Q1 2026; TTM through Mar 2026 was -$223.5 million, a 35.0% increase from a year earlier, with the FY2025 full-year figure at -$273.1 million, up 19.6% from the prior year.
• Operating Income rose to -$34.2 million in Q1 2026 per SNDX's latest filing, from -$62.5 million in the prior quarter.
• Across five years, Operating Income topped out at -$34.2 million in Q1 2026 and bottomed at -$96.4 million in Q4 2024.
• The 5-year median for Operating Income is -$57.4 million (2025), against an average of -$60.5 million.
• Across the five-year window, Operating Income slumped 143.9% in 2022 and jumped 59.17% in 2026, its largest moves.
• Year by year, Operating Income stood at -$42.0 million in 2022, then slumped by 85.34% to -$77.9 million in 2023, then dropped by 23.7% to -$96.4 million in 2024, then jumped by 35.09% to -$62.5 million in 2025, then soared by 45.32% to -$34.2 million in 2026.
• Per Business Quant, the three latest SNDX Operating Income figures stand at -$34.2 million (Q1 2026), -$62.5 million (Q4 2025), and -$57.4 million (Q3 2025).